Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 244.7 INR 3.22%
Market Cap: 722.9B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AUROPHARMA stock under the Base Case scenario is 1 407.24 INR. Compared to the current market price of 1 244.7 INR, Aurobindo Pharma Ltd is Undervalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AUROPHARMA Relative Value
Base Case
1 407.24 INR
Undervaluation 12%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.3
P/S
P/S
Price to Sales
2.3
vs History
19
vs Industry
48
Median 3Y
2
Median 5Y
1.9
Industry
2.4
Forward
2.2
More Details
20.1
P/E
P/E
Price to Earnings
20.1
vs History
31
vs Industry
24
Median 3Y
20.2
Median 5Y
14.9
Industry
20.5
Forward
19.4
More Details
44.1
P/OCF
P/OCF
Price to OCF
44.1
vs History
7
vs Industry
10
Median 3Y
26.7
Median 5Y
14.4
Industry
15.6
More Details
121.8
P/FCFE
P/FCFE
Price to FCFE
121.8
vs History
25
vs Industry
4
Median 3Y
102.6
Median 5Y
18.5
Industry
23.1
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
38
vs Industry
34
Median 3Y
1.9
Median 5Y
2.1
Industry
2
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
31
vs Industry
49
Median 3Y
1.8
Median 5Y
1.9
Industry
2.5
Forward
2.1
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
39
vs Industry
54
Median 3Y
3.1
Median 5Y
3.3
Industry
4.9
More Details
9.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.9
vs History
50
vs Industry
33
Median 3Y
9.6
Median 5Y
10.1
Industry
12.3
Forward
9.8
More Details
13.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.1
vs History
34
vs Industry
32
Median 3Y
13.3
Median 5Y
12.3
Industry
15.5
Forward
12.9
More Details
40.8
EV/OCF
EV/OCF
Enterprise Value to OCF
40.8
vs History
7
vs Industry
10
Median 3Y
24.2
Median 5Y
13.9
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-56.1
Median 5Y
-56.1
Industry
17.5
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
42
vs Industry
38
Median 3Y
1.5
Median 5Y
1.7
Industry
1.8
More Details

Multiples Across Competitors

AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
722.9B INR 2.3 20.1 9.9 13.1
US
Eli Lilly and Co
NYSE:LLY
716.1B USD 14.6 64.5 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.8B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
179.6B CHF 4 16.6 9.8 13.1
UK
AstraZeneca PLC
LSE:AZN
159.3B GBP 3.8 27 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
202.4B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.3B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average P/E: 24.2
20.1
15%
1.3
US
Eli Lilly and Co
NYSE:LLY
64.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
16.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
27
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average EV/EBITDA: 394.8
9.9
11%
0.9
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
9.8
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average EV/EBIT: 1 698.3
13.1
12%
1.1
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
CH
Novartis AG
SIX:NOVN
13.1
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
AUROPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
AUROPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AUROPHARMA stock valuation using valuation multiples.
Wall Street Estimates
AUROPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AUROPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.